Webinar Preview
Epilepsy is a chronic neurological disorder marked by recurring seizures and frequently accompanied by various comorbidities, including motor deficits, attention deficit hyperactivity disorder (ADHD), anxiety, depression and cognitive impairment.
Despite numerous available therapies, seizures in approximately 30 percent of epilepsy patients are not completely managed by available therapies. This webinar will delve into the urgent need to revamp therapy discovery strategies to better address drug-resistant epilepsy and highlight the importance of tackling the associated comorbidities.
Traditionally, antiseizure medication (ASM) discovery has relied on efficacy demonstrated with rodent in vivo seizure models such as maximal electroshock, subcutaneous pentylenetetrazol and kindling. However, recent advances in genetic sequencing technologies have facilitated an opportunity to better address the pressing medical needs of individuals with treatment-resistant epilepsy through the strategic use of syndrome-specific epilepsy models to discover novel compounds.
Next-generation drug discovery for epilepsy is likely to more comprehensively integrate syndrome-specific models into early-stage development processes. Despite over 30 marketed ASMs, a significant proportion of patients continue to suffer from pharmacoresistant epilepsy. This underscores the critical need to innovate discovery strategies to better address the needs of patients with drug-resistant epilepsy and developmental and epileptic encephalopathies.
Read Less…
Research has shown that kindling-induced epileptogenesis is characterized by significant behavioral and neurological changes. For example, behavioral assessments of kindled mice reveal substantial changes in activity and a decrease in risk assessment behaviors.
By attending this webinar, attendees will be able to gain insights into cutting-edge discovery strategies for drug-resistant epilepsy and the significance of addressing associated comorbidities. They will gain the knowledge to explain the role of syndrome-specific models in the development of innovative treatments for epilepsy. Additionally, they will be able to analyze recent research on kindling-induced epileptogenesis and neuroinflammation and evaluate strategies to enhance preclinical testing and improve translational success in clinical trials.
Register for this webinar today to understand how next-generation drug discovery is being pursued by integrating syndrome-specific models into epilepsy research.
Keywords: Drug Development, Drug Discovery, CRO, Epilepsy, Therapeutic Areas, CNS, Neurological Disease, Neurology, Neurological Disorder, Basic Research, DEE